- Home
- TIL vs GLSI Comparison
TIL vs GLSI Comparison
Compare TIL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- GLSI
- Stock Information
- Founded
- TIL 2018
- GLSI 2006
- Country
- TIL United States
- GLSI United States
- Employees
- TIL N/A
- GLSI N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- GLSI Health Care
- Exchange
- TIL Nasdaq
- GLSI Nasdaq
- Market Cap
- TIL 177.1M
- GLSI 145.2M
- IPO Year
- TIL 2021
- GLSI 2020
- Fundamental
- Price
- TIL $15.16
- GLSI $8.09
- Analyst Decision
- TIL Strong Buy
- GLSI Strong Buy
- Analyst Count
- TIL 5
- GLSI 1
- Target Price
- TIL $100.67
- GLSI $39.00
- AVG Volume (30 Days)
- TIL 82.0K
- GLSI 77.9K
- Earning Date
- TIL 11-13-2025
- GLSI 11-14-2025
- Dividend Yield
- TIL N/A
- GLSI N/A
- EPS Growth
- TIL N/A
- GLSI N/A
- EPS
- TIL N/A
- GLSI N/A
- Revenue
- TIL N/A
- GLSI N/A
- Revenue This Year
- TIL N/A
- GLSI N/A
- Revenue Next Year
- TIL N/A
- GLSI N/A
- P/E Ratio
- TIL N/A
- GLSI N/A
- Revenue Growth
- TIL N/A
- GLSI N/A
- 52 Week Low
- TIL $10.80
- GLSI $8.02
- 52 Week High
- TIL $42.79
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- TIL 34.33
- GLSI 27.29
- Support Level
- TIL $18.10
- GLSI $9.11
- Resistance Level
- TIL $20.11
- GLSI $9.51
- Average True Range (ATR)
- TIL 1.37
- GLSI 0.60
- MACD
- TIL -0.25
- GLSI -0.11
- Stochastic Oscillator
- TIL 0.00
- GLSI 2.48
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.